Ratings by Evercore ISI (Jonathan Miller)

More Stocks Rated by Evercore ISI
Date CompanySymbol Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
3/2/2026 Intellia Therapeutics NTLA Maintain In Line
(N/A)		  
 		   Details
11/25/2025 Aura Biosciences AURA New Coverage Outperform
(N/A)		 5.50
(5.60)		 1.82% Details
11/11/2025 Intellia Therapeutics NTLA Downgrade In Line
(Outperform)		 9.52
(13.44)		 41.18% Details
8/25/2025 Editas Medicine EDIT New Coverage Outperform
(N/A)		 2.80
(2.00)		 -28.57% Details
8/25/2025 Aura Biosciences AURA New Coverage Outperform
(N/A)		 6.55
(5.50)		 -16.03% Details
8/25/2025 Intellia Therapeutics NTLA New Coverage Outperform
(N/A)		 10.52
(9.52)		 -9.51% Details
8/25/2025 Enanta Pharmaceuticals ENTA New Coverage Outperform
(N/A)		 8.83
(13.54)		 53.34% Details
8/25/2025 Caribou Biosciences Inc. CRBU New Coverage In Line
(N/A)		 1.85
(1.82)		 -1.62% Details
4/30/2025 OnKure Therapeutics Inc. OKUR New Coverage Outperform
(N/A)		 2.53
(3.05)		 20.55% Details
11/27/2023 Gracell Biotechnologies Inc GRCL New Coverage Outperform
(N/A)		 5.05
(10.25)		 102.97% Details
10/11/2023 RayzeBio RYZB New Coverage Outperform
(N/A)		 21.03
(62.49)		 197.15% Details
3/31/2023 Gritstone Oncology GRTS New Coverage Outperform
(N/A)		 2.59
(0.03)		 -98.84% Details
9/2/2022 ProKidney Corp. PROK New Coverage Outperform
(N/A)		 9.67
(2.30)		 -76.22% Details
4/27/2022 Vaxxinity VAXX New Coverage In Line
(N/A)		 3.61
(0.01)		 -99.72% Details
11/24/2021 Entrada Therapeutics TRDA New Coverage Outperform
(N/A)		 24.23
(12.58)		 -48.08% Details
7/1/2020 Gamida Cell Ltd. GMDA New Coverage Outperform
(N/A)		 4.46
(0.03)		 -99.33% Details
9/12/2019 Tocagen Inc. TOCA Downgrade In Line
(Outperform)		 4.18
(1.26)		 -69.86% Details